Section Arrow
NBIX.NASDAQ
- Neurocrine Biosciences
Quotes are at least 15-min delayed:2025/05/10 17:31 EDT
Last
 115.71
-1.81 (-1.54%)
Day High 
119.67 
Prev. Close
117.52 
1-M High
130.46 
Volume 
1.32M 
Bid
100
Ask
135.09
Day Low
115.66 
Open
118.04 
1-M Low
84.23 
Market Cap 
11.63B 
Currency USD 
P/E 39.84 
%Yield -- 
10-SMA 111.22 
20-SMA 104.89 
50-SMA 107.51 
52-W High 157.9799 
52-W Low 84.23 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
2.95/6.08
Enterprise Value
12.09B
Balance Sheet
Book Value Per Share
25.62
Cash Flow
Cash Flow Yield
0.04
Income Statement
Total Revenue
2.36B
Operating Revenue Per Share
18.03
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SHPHShuttle Pharmaceuticals Holdings Inc0.2325-0.0375-13.89%-- 
PTPIPetros Pharmaceuticals Inc0.1201-0.0053-4.23%-- 
VTRSViatris8.77-0.32-3.52%227.2PE
TEVATeva Pharmaceutical Industries Limited16.93-1.14-6.31%-- 
IXHLIncannex Healthcare0.1135+0.0009+0.80%-- 
Quotes are at least 15-min delayed:2025/05/10 17:31 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.